School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China; Guangdong Provincial Key Laboratory of Advanced Drug Delivery, Guangdong Pharmaceutical University, Guangzhou, China; Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, Guangdong Pharmaceutical University, Guangzhou, China.
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
Eur J Pharm Sci. 2019 Jan 1;126:11-22. doi: 10.1016/j.ejps.2018.02.031. Epub 2018 Feb 28.
Drug delivery to the inner ear by nanomedicine strategies has emerged as an effective therapeutic approach for the management of inner ear diseases including hearing and balance disorders. It is well accepted that substance enters the perilymph from the middle ear through the round window membrane (RWM), but the passage through the oval window (OW) has long been neglected. Up to now, researchers still know little about the pathway via which nanoparticles (NPs) enter the inner ear or how they reach the inner ear following local applications. Herein, we engineered fluorescence traceable chitosan (CS) NPs, investigated the NP distribution within cochlear and vestibular organs, and assessed the availability of RWM and OW pathways to NP transport. Intriguingly, there were high levels of CS NPs in vestibular hair cells, dark cells and supporting cells, but negligible ones in cochlear hair cells and epithelial cells after intratympanic administration. However, the NPs were visualized in two cell models, L929 and HEI-OC1 cell lines, and in the hair cells of cochlear explants after co-incubation in vitro. These combined studies implied that CS NPs might enter the vestibule directly through the OW and then preferentially accumulated in the cells of vestibular organs. Thus, in vivo studies were carried out and clearly revealed that CS NPs entered the inner ear through both the RWM and OW, but the latter played a governing role in delivering NPs to the vestibule with vivid fluorescence signals in the thin bone of the stapes footplate. Overall, these findings firstly suggested that the OW, as a royal gate, afforded a convenient access to facilitate CS NPs transport into inner ear, casting a new light on future clinical applications of NPs in the effective treatment of vestibular disorders by minimizing the risk of hearing loss associated with cochlear hair cell pathology.
纳米医学策略向内耳给药已成为治疗内耳疾病(包括听力和平衡障碍)的有效治疗方法。人们普遍认为,物质通过圆窗膜(RWM)从中耳进入外淋巴,但通过卵圆窗(OW)的途径长期以来一直被忽视。到目前为止,研究人员仍然对外来体通过何种途径进入内耳以及局部应用后如何到达内耳知之甚少。在此,我们构建了荧光可追踪壳聚糖(CS)纳米颗粒,研究了 CS 纳米颗粒在耳蜗和前庭器官中的分布,并评估了 RWM 和 OW 途径用于 NP 转运的可行性。有趣的是,经鼓室内给药后,前庭毛细胞、黑细胞和支持细胞中 CS 纳米颗粒水平较高,而耳蜗毛细胞和上皮细胞中则可忽略不计。然而,在体外共孵育后,在两个细胞模型(L929 和 HEI-OC1 细胞系)和耳蜗外植体的毛细胞中观察到了 NPs。这些综合研究表明,CS NPs 可能通过 OW 直接进入前庭,然后优先积聚在前庭器官的细胞中。因此,进行了体内研究,清楚地表明 CS NPs 通过 RWM 和 OW 进入内耳,但后者在将 NPs 递送至前庭中起主导作用,在镫骨足板的薄骨中呈现出生动的荧光信号。总的来说,这些发现首次表明,OW 作为一个皇家之门,为 CS NPs 进入内耳提供了便利的通道,为将来通过最小化与耳蜗毛细胞病理相关的听力损失风险,将 NPs 有效应用于前庭疾病的治疗提供了新的思路。